BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
| Presentation details: | |
| Date: | Monday, January 9, 2023 |
| Time: | 1:30 – 2:10 p.m. Pacific Standard Time (PST) |
| Moderator: | Eric Joseph, Ph.D. |
| Location: | Borgia Room, Westin St. Francis Hotel, San Francisco |
| HilleVax Participant: | Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer |
| Webcast & Audio Visual: | https://jpmorgan.metameetings.net/events/healthcare23/general_signin?gpu_only=true |
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.
Contact:
Shane Maltbie
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-617-213-5054
| Last Trade: | US$1.87 |
| Daily Change: | 0.01 0.54 |
| Daily Volume: | 84,361 |
| Market Cap: | US$93.140M |
November 07, 2024 August 08, 2024 July 08, 2024 May 09, 2024 March 20, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
